Tuberculosis

Our work on tuberculosis is led by colleagues at HE²RO.  For more information, please visit http://www.heroza.org/themes/tb-2/. Information on the national TB cohort can be found at   https://sites.bu.edu/hiv/epidemiology/big-data/.

Publications and other documents

Reduction in initiations of tuberculosis treatment in South Africa during the COVID pandemic. Benade M, Long LC, Meyer-Rath G, Miot J, Evans D, Tucker JM, Moultrie H, Rosen S. PLOS Glob Public Health. 2022 Oct 11;2(10):e0000559. doi: 10.1371/journal.pgph.0000559. PMID: 36962535; PMCID: PMC10021649.

Adaptation of WHO’s generic tuberculosis patient cost instrument for a longitudinal study in Africa. Evans D, van Rensburg C, Govathson C, Ivanova O, Riess F, Siroka A, Sillah AK, Ntinginya NE, Jani I, Sathar F, Rosen S, Sanne I, Rachow A, Lonnruth K. Glob Health Action. 2021 Jan 1;14(1):1865625. doi: 10.1080/16549716.2020.1865625. PMID: 33491593; PMCID: PMC7850383.

Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis. Masuku SD, Berhanu R, Van Rensburg C, Ndjeka N, Rosen S, Long L, Evans D, Nichols BE. Int J Tuberc Lung Dis. 2020 Apr 1;24(4):376-382. doi: 10.5588/ijtld.19.0409. PMID: 32317060; PMCID: PMC7656447.

Data quality assessment of a South African electronic registry for drug-resistant TB, 2015-2016. Jamieson L , Evans D, Berhanu R, Ismail N, Aucock S, Wallengren K, Long L. Public Health Action. 2021 Mar 21;11(1):33-39. doi: 10.5588/pha.20.0031. PMID: 33777719; PMCID: PMC7987250.

Treatment outcomes among children, adolescents, and adults on treatment for tuberculosis in two metropolitan municipalities in Gauteng Province, South Africa. Berry KM, Rodriguez CA, Berhanu RH, Ismail N, Mvusi L, Long L, Evans D.BMC Public Health. 2019 Jul 22;19(1):973. doi: 10.1186/s12889-019-7257-4. PMID: 31331311; PMCID: PMC6647101.

Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa. van Rensburg C, Berhanu R, Hirasen K, Evans D, Rosen S, Long L. PLoS One. 2019 Jun 6;14(6):e0217820. doi: 10.1371/journal.pone.0217820. PMID: 31170207; PMCID: PMC6553851.

The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Sineke T, Evans D, Schnippel K, van Aswegen H, Berhanu R, Musakwa N, Lonnmark E, Long L, Rosen SHealth and QOL Outcomes 2019; 17:94.

Impact of Xpert MTB/RIF on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. Evans D, SinekeT, Schnippe K, Berhanu R, Govathson C, Black A, Long L, Rosen S. BMC Health Serv Res 2018;18:973.

High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. Hirasen K, Berhanu R, Evans D, Rosen S, Sanne I, Long L. PloS One 2018; 13: e0205463.

The costs and outcomes of paediatric tuberculosis treatment at primary health clinics in Johannesburg, South Africa. Budgell E, Evans D, Mohamed R, Ive P, Long L, Rosen S. S Afr Med J. 2018 Apr 25;108(5):423-431. doi: 10.7196/SAMJ.2018.v108i5.12802. PMID: 29843858.

Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa. Evans D, Schippel K, Govathson C, Sineke T, Black A, Long L, Berhanu R, Rosen S.PLOS One 2017; 12(7): e0181238.

Early outcomes of decentralized care for rifampicin-resistant tuberculosis in Johannesburg, South Africa. Berhanu R, Schnippel K, Mohr E, Hirasen K, Evans D, Rosen S, Sanne I. PLoS One 2016;11: e0164974.